Literature DB >> 2682727

Leponex--associated granulocytopenia: a review of the situation.

P Krupp1, P Barnes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2682727     DOI： 10.1007/bf00442575

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  12 in total

Review 1.  COMPLICATIONS FROM PSYCHOTHERAPEUTIC DRUGS--1964.

Authors:  L E HOLLISTER
Journal:  Clin Pharmacol Ther       Date:  1964 May-Jun       Impact factor: 6.875

2.  Chlorpromazine: ten years' experience.

Authors:  F J AYD
Journal:  JAMA       Date:  1963-04-06       Impact factor: 56.272

3.  [Agranulocytosis due to neuropsychiatric phenothiazine therapy].

Authors:  H HIPPIUS; K KANIG
Journal:  Arztl Wochensch       Date:  1958-06-06

4.  Preliminary report on 500 patients treated with thorazine at Rochester State Hospital.

Authors:  B POLLACK
Journal:  Psychiatr Q       Date:  1955-07

5.  Clozapine-induced agranulocytosis. A genetic and epidemiologic study.

Authors:  A de la Chapelle; C Kari; M Nurminen; S Hernberg
Journal:  Hum Genet       Date:  1977-06-30       Impact factor: 4.132

Review 6.  Immune and toxic mechanisms in drug-induced agranulocytosis.

Authors:  A V Pisciotta
Journal:  Semin Hematol       Date:  1973-10       Impact factor: 3.851

7.  Agranulocytosis, leukopenia, and psychotropic drugs.

Authors:  R Litvak; R Kaelbling
Journal:  Arch Gen Psychiatry       Date:  1971-03

Review 8.  Agranulocytosis induced by certain phenothiazine derivatives.

Authors:  A V Pisciotta
Journal:  JAMA       Date:  1969-06-09       Impact factor: 56.272

9.  Agranulocytosis and phenothiazines.

Authors:  A Mandel; M Gross
Journal:  Dis Nerv Syst       Date:  1968-01

10.  Clozapine-induced agranulocytosis: a situation report up to August 1976.

Authors:  B Anderman; R W Griffith
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953
View more
  18 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

Review 2.  Mechanisms of clozapine-induced agranulocytosis.

Authors:  S L Gerson; H Meltzer
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

3.  Development of the Clozaril Patient Management System.

Authors:  B Bastani; L D Alphs; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Continuing clozapine treatment despite neutropenia.

Authors:  David Esposito; Frédéric Rouillon; Frédéric Limosin
Journal:  Eur J Clin Pharmacol       Date:  2004-11-30       Impact factor: 2.953

5.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

6.  EEG alterations in patients treated with clozapine in relation to plasma levels.

Authors:  C Haring; C Neudorfer; J Schwitzer; M Hummer; A Saria; H Hinterhuber; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 7.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

8.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 10.  Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Authors:  Michael Berk; Joanna Fitzsimons; Timothy Lambert; Christos Pantelis; Jayashri Kulkarni; David Castle; Elizabeth W Ryan; Sean Jespersen; Pat McGorry; Gregor Berger; Bill Kuluris; Tom Callaly; Seetal Dodd
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.